Tissue Targeted Medicines, Designed In Vivo.
Manifold is using in vivo biologics design to unlock a new era of tissue-targeted medicines.
Our mDesign platform combines an industry-first 100-plex pooled in vivo screening technology with AI-guided protein design to sculpt the biodistribution, pharmacokinetics, and other drug-like properties of protein-based therapeutics directly in living systems.
At Manifold, we are advancing a wave of potent, tolerable medicines for the brain and beyond, and reinventing drug discovery using mDesign.
mDesign: How it Works
AI-Guided Protein Design
Generative design of libraries and antibodies combined with high-throughput display
In Vivo Multiplexing
Evaluate distribution of 100 protein designs simultaneously in a single animal
Tissue-targeted Biologics Pipeline
Unlocking potent, tolerable medicines
Powered by mCodes
High-throughput, 100plex in vivo screening is made possible by mCodes: a first-of-its-kind protein barcoding and quantitation technology invented by Manifold. mCodes are specific, sensitive, inert, and quantitative - serving as unique identifiers to track and quantitate large pools of biotherapeutic drug candidates in complex living systems.
Shuttled Therapeutics for Neuromedicine and Beyond
A renaissance has begun in neuroscience with recent clinical data supporting a number of promising targets for therapeutic intervention.
Yet, delivery of diverse modalities across the blood-brain barrier and to specific regions of the brain remains a challenge that limits efficacy and creates burdens on routes of administration.
Manifold has moved quickly using in vivo design to establish a brain shuttling platform and is now building a pipeline of medicines for neurological disorders with immense unmet need.
Discovery
Optimization
Expanding Shuttle Portfolio
Our pipeline is built on top of our growing portfolio of tissue-specific shuttles. These engineered protein delivery vehicles allow us to deliver a wide range of therapeutic payloads to targeted tissues with high specificity and efficiency.
Our current library includes:
- Brain shuttles optimized for crossing the blood-brain barrier
- Emerging shuttles for other tissue types, expanding our therapeutic reach
Broad Therapeutic Potential of mDesign
Enhanced therapeutic delivery
- Shuttles for brain and peripheral targets
- Conditionally-activated biologics
- Half-life extension
- Subcutaneous administration
- Improved translation of in vivo-encoded biologics
Partnership Opportunities
We're open to collaborations that leverage our mDesign™ platform and shuttle library to develop novel targeted therapies. Whether you're interested in neuroscience or other therapeutic areas, we offer flexible partnership models to accelerate your drug discovery efforts.
Our Team
With deep expertise spanning high-throughput molecular biology, ML-guided protein engineering and drug discovery we're united by a common mission: to create life-changing medicines by unlocking in vivo drug design at scale.
Founders & Leadership
